Implications of Immunotherapy in Hepatobiliary Tumors.
Cytotoxic T-lymphocyte-associated protein 4 antibody
Hepatocellular carcinoma
Immune checkpoint inhibitors
Immunotherapy
Programmed cell death protein 1 antibody
Programmed death ligand 1 antibody
Targeted therapy
Journal
Visceral medicine
ISSN: 2297-4725
Titre abrégé: Visc Med
Pays: Switzerland
ID NLM: 101681546
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
04
12
2018
accepted:
09
01
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide. Upon ineligibility for resection, liver transplantation, or locoregional therapies, sorafenib has been the only systemic treatment option of advanced HCC for more than a decade. Immunotherapy is an evolving HCC treatment option that has shown promise in treatment efficacy at an acceptable safety profile during several preceding phase I/II trials. Numerous clinical trials of immune checkpoint inhibitors (ICPIs) alone, in combination of two, or combined with other targeted or locoregional therapies are ongoing. Encouraging results of two-phase III trials testing pembrolizumab or nivolumab versus standard care therapy even resulted in Food and Drug Administration approval for second-line treatment of advanced HCC. ICPIs may open new avenues to the treatment of hepatobiliary tumors, alone or in combination.
Identifiants
pubmed: 31312646
doi: 10.1159/000496755
pii: vis-0035-0018
pmc: PMC6597927
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
18-26Déclaration de conflit d'intérêts
A. Gottlieb, A. Canbay: no conflicts of interest to declare. J. Best: consultant for Biocompatibles UK, Eisai, BMS; speaker honoraria: Biocompatibles UK, Abbvie. No funding was received.
Références
Eur J Cancer. 2018 Sep;100:135-136
pubmed: 29970352
Liver Cancer. 2018 Mar;7(1):1-19
pubmed: 29662829
Lancet Oncol. 2015 Jan;16(1):e11
pubmed: 25638546
Clin Cancer Res. 2016 Mar 15;22(6):1385-94
pubmed: 26500236
Transl Gastroenterol Hepatol. 2018 Jul 12;3:40
pubmed: 30148225
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Cancer Manag Res. 2018 Oct 02;10:4113-4123
pubmed: 30323667
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Eur J Cancer. 2013 Nov;49(16):3412-9
pubmed: 23809766
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Ann Oncol. 2017 Mar 1;28(3):450-451
pubmed: 28137742
J Clin Oncol. 2013 Oct 1;31(28):3509-16
pubmed: 23980090
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Onco Targets Ther. 2016 Aug 12;9:5023-39
pubmed: 27574444
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
Eur J Radiol. 2016 Jan;85(1):103-112
pubmed: 26724654
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
JAMA. 2014 Jul 2;312(1):57-67
pubmed: 25058218
J Hepatol. 2014 Aug;61(2):318-24
pubmed: 24703956
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Gastrointest Cancer. 2017 Sep;48(3):282-285
pubmed: 28624974
Liver Cancer. 2018 Sep;7(3):215-224
pubmed: 30319981
Br J Cancer. 2018 Jul;119(1):19-26
pubmed: 29808014
Eur J Cancer. 2017 Aug;81:17-25
pubmed: 28591675
Gastroenterology. 2014 May;146(5):1193-207
pubmed: 24412289
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
Hepatology. 2011 Apr;53(4):1206-16
pubmed: 21480325
Hepat Oncol. 2016 Aug;3(3):187-189
pubmed: 30191039
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Jpn J Clin Oncol. 2018 Aug 1;48(8):703-711
pubmed: 29893894
Liver Cancer. 2017 Nov;6(4):253-263
pubmed: 29234629
N Engl J Med. 2018 Oct 04;379(14):1384-1385
pubmed: 30281991
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135
pubmed: 28503645
Cancer Immunol Immunother. 2018 May;67(5):843-853
pubmed: 29500633
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Oncotarget. 2017 Aug 24;8(44):77415-77423
pubmed: 29100397
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Liver Cancer. 2016 Jul;5(3):221-32
pubmed: 27493897
J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):59-63
pubmed: 19224164
J Hepatol. 2015 Jun;62(6):1420-9
pubmed: 25733155
J Clin Oncol. 2013 Nov 10;31(32):4067-75
pubmed: 24081937
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
BMJ Open. 2018 Oct 18;8(10):e021269
pubmed: 30341113
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterology. 2016 Apr;150(4):998-1008
pubmed: 26752112